ANIX Stock Analysis: Buy, Sell, or Hold?
ANIX - Anixa Biosciences, Inc.
$2.63
0.15 (6.28%)
▲
5d:
+6.71%
30d:
-9.17%
90d:
-7.57%
BUY
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Jun 10, 2026
0d
Get Alerted When ANIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ANIX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ANIX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ANIX is currently trading at $2.62, which is considered fair relative to its 30-day fair value range of $2.51 to $2.88.
Technical Outlook: Technically, ANIX is in a downtrend. Immediate support is located at $2.32, while resistance sits at $2.75. The stock is showing strong short-term momentum, up 6.3% recently.
Market Sentiment: ANIX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+345.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ANIX is in a downtrend. Immediate support is located at $2.32, while resistance sits at $2.75. The stock is showing strong short-term momentum, up 6.3% recently.
Market Sentiment: ANIX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+345.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.51 -
$2.88
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
64.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.3%)
- BULLISH: Trading 345.3% below Wall St target ($11.00)
Trading Range Analysis
30-Day Trading Range
$2.51 -
$2.88
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.30
(11.3%)
Support & Resistance Levels
Support Level
$2.32
Resistance Level
$2.75
Current Trend
Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.86
Wall Street Target
$11.00
(+345.3%)
Share & Embed Analysis
Last updated: June 15, 2026 10:09 AM ET
Data refreshes hourly during market hours. Next update: 11:09 AM
Data refreshes hourly during market hours. Next update: 11:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANIX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Arnold M Baskies
BUY
10000 shares
2026-01-28
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$439 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1029 | 63 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 48 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 51 HOLD |
